Literature DB >> 3346626

Selective acceptance of MHC class I-deficient tumor grafts in the brain.

H G Ljunggren1, T Yamasaki, P Collins, G Klein, K Kärre.   

Abstract

H-2-deficient (H-2-) tumor variants were accepted equally well compared with H-2+ wild-type cells in the brain of syngeneic mice, while the H-2- cells were selectively eliminated when inoculated extracranially. This indicates a specific absence or suppression of the defense against MHC class I-deficient cells in the brain, suggested to be mediated by NK cells. In contrast, T cell-mediated immune reactions could clearly be detected in the brain under the same experimental conditions. This was shown in control experiments where H-2+ tumor cells were rejected from the brain of preimmunized or allogeneic mice. The present findings may be important for the understanding of neurotropic virus infections, immunology and immunotherapy of brain tumors, as well as for the growing interest in tissue grafting within the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3346626      PMCID: PMC2188854          DOI: 10.1084/jem.167.2.730

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  13 in total

1.  Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement.

Authors:  L A Lampson; W F Hickey
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

2.  The immune system and the nervous system.

Authors:  J A Aarli
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

3.  Mouse brain: an immunologically privileged site for natural resistance against lymphoma cells.

Authors:  A Circolo; R Bianchi; B Nardelli; P Rivosecchi-Merletti; E Bonmassar
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

Review 4.  Immunobiologic aspects of the brain and human gliomas. A review.

Authors:  C J Wikstrand; D D Bigner
Journal:  Am J Pathol       Date:  1980-02       Impact factor: 4.307

5.  Distribution and quantitation of HLA-ABC and DR (Ia) antigens on human kidney and other tissues.

Authors:  K A Williams; D N Hart; J W Fabre; P J Morris
Journal:  Transplantation       Date:  1980-04       Impact factor: 4.939

6.  H-2 associated resistance to leukaemia transplantation: natural killing in vivo.

Authors:  G A Carlson; D Melnychuk; M J Meeker
Journal:  Int J Cancer       Date:  1980-01-15       Impact factor: 7.396

7.  Experimental strategies and interpretations in the analysis of changes in MHC gene expression during tumour progression. Opposing influences of T cell and natural killer mediated resistance?

Authors:  H G Ljunggren; K Kärre
Journal:  J Immunogenet       Date:  1986 Apr-Jun

8.  Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

Authors:  K Kärre; H G Ljunggren; G Piontek; R Kiessling
Journal:  Nature       Date:  1986 Feb 20-26       Impact factor: 49.962

9.  Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice.

Authors:  G Cudkowicz; M Bennett
Journal:  J Exp Med       Date:  1971-12-01       Impact factor: 14.307

10.  Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism.

Authors:  H G Ljunggren; K Kärre
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  8 in total

Review 1.  Role of major histocompatibility complex class-I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice.

Authors:  P Höglund; H G Ljunggren; K Kärre; G Jay
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

2.  Intracerebral inflammatory response to experimental brain contusion.

Authors:  S Holmin; T Mathiesen; J Shetye; P Biberfeld
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

3.  Detection of Eber-1 RNA in primary brain lymphomas in immunocompetent and immunocompromised patients.

Authors:  R Bashir; B McManus; C Cunningham; D Weisenburger; F Hochberg
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Expression of beta 2-microglobulin by human benign and malignant mesenchymal and neurogenic tumours.

Authors:  B L Petersen; O Braendstrup
Journal:  Int J Exp Pathol       Date:  1993-08       Impact factor: 1.925

5.  Altered natural killer cell repertoire in Tap-1 mutant mice.

Authors:  H G Ljunggren; L Van Kaer; H L Ploegh; S Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

Review 6.  Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self" recognition.

Authors:  Karl-Johan Malmberg; Ebba Sohlberg; Jodie P Goodridge; Hans-Gustaf Ljunggren
Journal:  Immunogenetics       Date:  2017-07-11       Impact factor: 2.846

7.  Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex-encoded transporter gene.

Authors:  L Franksson; E George; S Powis; G Butcher; J Howard; K Kärre
Journal:  J Exp Med       Date:  1993-01-01       Impact factor: 14.307

Review 8.  Paths taken towards NK cell-mediated immunotherapy of human cancer-a personal reflection.

Authors:  Hans-Gustaf Ljunggren
Journal:  Scand J Immunol       Date:  2020-11-20       Impact factor: 3.487

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.